Replies to post #136367 on Anavex Life Sciences Corp (AVXL)

[polarbear77]

Mikesc it’s possible that the results presented in the below article may be reaching the scientific community & biotech analysts [soon to be published in the Alzheimer’s Association’s Journal (as posted on ihub by graniteguy 2 days ago) regarding our 3-71 compound and our sigma-1 receptor agonist efficacy results/MOA].


“Results
AF710B long-term treatment reverted the cognitive deficits associated with advanced Alzheimer-like amyloid neuropathology in Tg rats. These effects were accompanied by reductions in amyloid pathology and markers of neuroinflammation and increases in amyloid cerebrospinal fluid clearance and levels of a synaptic marker. Importantly, these effects were maintained following a 5-week interruption of the treatment.”

http://www.alzheimersanddementia.com/article/S1552-5260(17)33851-7/fulltext

AF710B, an M1/sigma-1 receptor agonist with long-lasting disease-modifying properties in a transgenic rat model of Alzheimer's disease